NASDAQ:CLSN

Celsion Stock Forecast, Price & News

$1.24
-0.08 (-6.06 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.24
$1.32
50-Day Range
$0.98
$1.54
52-Week Range
$0.43
$5.26
Volume1.97 million shs
Average Volume11.65 million shs
Market Capitalization$107.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96
30 days | 90 days | 365 days | Advanced Chart
Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for Celsion and its competitors with MarketBeat's FREE daily newsletter.


Celsion logo

About Celsion

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.43 out of 5 stars

Medical Sector

683rd out of 2,100 stocks

Pharmaceutical Preparations Industry

335th out of 830 stocks

Analyst Opinion: 3.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Celsion (NASDAQ:CLSN) Frequently Asked Questions

Is Celsion a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Celsion stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLSN, but not buy additional shares or sell existing shares.
View analyst ratings for Celsion
or view top-rated stocks.

What stocks does MarketBeat like better than Celsion?

Wall Street analysts have given Celsion a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Celsion wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Celsion's next earnings date?

Celsion is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Celsion
.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) posted its quarterly earnings data on Friday, May, 14th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.03. Celsion had a negative trailing twelve-month return on equity of 67.84% and a negative net margin of 4,423.40%.
View Celsion's earnings history
.

How has Celsion's stock price been impacted by COVID-19?

Celsion's stock was trading at $0.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CLSN shares have increased by 25.3% and is now trading at $1.24.
View which stocks have been most impacted by COVID-19
.

When did Celsion's stock split? How did Celsion's stock split work?

Celsion shares reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CLSN?

2 brokerages have issued 1 year price objectives for Celsion's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Celsion's share price to reach $4.00 in the next year. This suggests a possible upside of 222.6% from the stock's current price.
View analysts' price targets for Celsion
or view top-rated stocks among Wall Street analysts.

Who are Celsion's key executives?

Celsion's management team includes the following people:
  • Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 70, Pay $1M)
  • Mr. Jeffrey W. Church CPA, CPA, CFO, Exec. VP & Corp. Sec. (Age 64, Pay $522.62k)
  • Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 61, Pay $484.75k)
  • Dr. Nicholas Borys, Exec. VP & Chief Medical Officer (Age 62, Pay $582.24k)
  • Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 63)
  • Ms. Marianne M. Lambertson, VP of Communications & Investor Relations

Who are some of Celsion's key competitors?

What other stocks do shareholders of Celsion own?

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Who are Celsion's major shareholders?

Celsion's stock is owned by a variety of retail and institutional investors. Top institutional investors include Altium Capital Management LP (4.04%), Morgan Stanley (2.24%), BlackRock Inc. (1.31%), Geode Capital Management LLC (0.59%), Eudaimonia Partners LLC (0.17%) and Northern Trust Corp (0.14%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Donald P Braun, Frederick J Fritz and Jeffrey Wayne Church.
View institutional ownership trends for Celsion
.

Which major investors are selling Celsion stock?

CLSN stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC.
View insider buying and selling activity for Celsion
or view top insider-selling stocks.

Which major investors are buying Celsion stock?

CLSN stock was acquired by a variety of institutional investors in the last quarter, including Altium Capital Management LP, Morgan Stanley, BlackRock Inc., Geode Capital Management LLC, Virtu Financial LLC, XTX Topco Ltd, Northern Trust Corp, and HRT Financial LP. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Donald P Braun, Frederick J Fritz, and Jeffrey Wayne Church.
View insider buying and selling activity for Celsion
or or view top insider-buying stocks.

How do I buy shares of Celsion?

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celsion's stock price today?

One share of CLSN stock can currently be purchased for approximately $1.24.

How much money does Celsion make?

Celsion has a market capitalization of $107.33 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-21,480,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does Celsion have?

Celsion employs 27 workers across the globe.

What is Celsion's official website?

The official website for Celsion is www.celsion.com.

Where are Celsion's headquarters?

Celsion is headquartered at 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648.

How can I contact Celsion?

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at (609) 896-9100 or via email at [email protected]


This page was last updated on 6/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.